At its recent earnings call, Lotus Pharmaceutical reaffirmed its 2025 goals: 5–6% revenue growth, ~60% gross margin, and an operating margin exceeding 30%.

Key Financial & Market Drivers:

• Lenalidomide (Lena): After a slow start in Q1, the blockbuster blood cancer drug returned to double-digit growth in October. While the U.S. market faces increased price competition as it fully opens in 2026, Lotus expects volume increases to sustain revenue. Q1 2026 will be a critical observation period for market dynamics.
• Asian Growth: Revenue in Asia grew 16% YoY, driven by the successful integration of Teva's Thai business and Sanofi's Alpha Choay in Vietnam.
• Pipeline Momentum: Nintedanib (targeting pulmonary fibrosis) and Enzalutamide (prostate cancer) are expected to reach peak sales of $50 million each. Nintedanib is slated for a European launch first, followed by the U.S. in 2026.
• Strategic Milestone: With regulatory approval secured, the Alvogen US acquisition is on track to close by year-end. This merger is expected to propel Lotus into the ranks of the top 20 global pharmaceutical companies.

Resource:美時今年營運向上目標不變，血癌藥明年營收有撐、Q1重點觀察期